Affinage

FZD7

Frizzled-7 · UniProt O75084

Length
574 aa
Mass
63.6 kDa
Annotated
2026-04-28
84 papers in source corpus 30 papers cited in narrative 30 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FZD7 is a seven-transmembrane Frizzled family receptor that serves as a central hub for both canonical Wnt/β-catenin and non-canonical Wnt signaling, governing stem cell self-renewal, differentiation, cell polarity, and cytoskeletal dynamics across diverse tissue contexts. In canonical signaling, FZD7 partners with LRP6 to transduce Wnt3a and other ligands, stabilizing β-catenin and activating TCF-dependent transcription; selective FZD7–LRP6 engagement is sufficient to drive mesendodermal differentiation of human pluripotent stem cells and is required for maintaining the pluripotent state (PMID:33331818, PMID:24474766, PMID:21532620). In non-canonical pathways, FZD7 engages Wnt11 or Wnt5a to activate PCP effectors (Vangl1, DAAM1, Rho-ROCK-Myosin II) controlling cell migration and invasion, and independently signals through Gαs/PI3K/Akt or JAK1/STAT3 axes depending on cellular context (PMID:33082334, PMID:22179044, PMID:38246919, PMID:37336284). FZD7 protein levels are regulated transcriptionally by ΔNp63, BCL6, Notch3, and PU.1, post-transcriptionally by the m6A reader YTHDF1, and post-translationally by ZNRF3-mediated ubiquitination and lysosomal degradation that depends on the LRP6 ectodomain (PMID:25241036, PMID:37060074, PMID:32788173, PMID:28600110, PMID:32015160).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2008 Medium

    Establishing that FZD7 is functionally important in human embryonic stem cells answered whether Frizzled receptors play active roles in pluripotency maintenance, rather than being passive markers of undifferentiated cells.

    Evidence shRNA knockdown of FZD7 in hESCs with OCT4 loss and morphology change

    PMID:18681827

    Open questions at the time
    • Downstream pathway (canonical vs. non-canonical) not resolved
    • No rescue experiment to confirm specificity
    • Mechanism linking FZD7 to OCT4 expression unknown
  2. 2011 High

    Demonstrating that FZD7 is the receptor required for canonical Wnt/β-catenin signaling in triple-negative breast cancer, and independently that Wnt7a–Fzd7 activates Akt/mTOR via a Gαs–PI3K complex in myofibers, established FZD7 as a bifunctional receptor capable of engaging distinct intracellular signaling cascades depending on ligand and cell context.

    Evidence shRNA knockdown with β-catenin/TCF reporter in TNBC (PMID:21532620); Co-IP of Fzd7–Gαs–PI3K complex with Akt/mTOR readout in myotubes (PMID:22179044)

    PMID:21532620 PMID:22179044

    Open questions at the time
    • Whether Gαs–PI3K complex forms in non-muscle contexts unknown
    • Structural basis for ligand-selective pathway activation not determined
  3. 2014 High

    Identifying ΔNp63 as a direct transcriptional activator of FZD7 in mammary stem cells, and showing that FZD7-specific antibody blockade disrupts hESC pluripotency, established how FZD7 expression is controlled and confirmed its non-redundant receptor function in stem cell biology.

    Evidence ΔNp63 gain/loss-of-function with FZD7 expression and mammary stem cell assays (PMID:25241036); FZD7-specific Fab blocking antibody and shRNA in hESCs (PMID:24474766); FZD7 KD with RhoA/Rac1 activity assays in ovarian cancer (PMID:25032869)

    PMID:24474766 PMID:25032869 PMID:25241036

    Open questions at the time
    • Whether ΔNp63 regulation of FZD7 operates in non-mammary stem cells unknown
    • How FZD7 simultaneously regulates canonical and PCP outputs in the same cell not resolved
  4. 2016 High

    Conditional endothelial deletion of Fzd7 and identification of Notch3-specific and TAZ-dependent FZD7 signaling expanded the receptor's known physiological roles to angiogenesis and glioma, and revealed additional upstream regulators and downstream effectors.

    Evidence fzd7ECKO mice with retinal angiogenesis defects rescued by LiCl (PMID:27758766); NOTCH3-specific, CSL-independent FZD7 regulation (PMID:26847503); TAZ epistasis in glioma (PMID:27852064)

    PMID:26847503 PMID:27758766 PMID:27852064

    Open questions at the time
    • Mechanism of CSL-independent Notch3 regulation of FZD7 promoter not defined
    • Direct physical interaction between FZD7 signaling and TAZ not biochemically demonstrated
  5. 2017 High

    Showing that RSPO2 promotes ZNRF3-mediated ubiquitination and lysosomal degradation of FZD7 while Wnt5a protects it from degradation answered how FZD7 surface levels are post-translationally controlled and how R-spondin modulates non-canonical signaling.

    Evidence Co-IP and ubiquitination assays of RSPO2–ZNRF3–FZD7; Wnt5a competition for FZD7 binding

    PMID:28600110

    Open questions at the time
    • Whether other E3 ligases besides ZNRF3 target FZD7 unknown
    • Structural basis of RSPO2–FZD7 interaction not resolved
  6. 2020 High

    Multiple studies converged to define the full scope of FZD7 non-canonical signaling, showing WNT11–FZD7–DAAM1–Rho-ROCK-Myosin II drives melanoma invasion, Wnt5a–FZD7 activates STAT3/YAP1/Col6a1 in breast cancer stemness, and that selective FZD7–LRP6 bispecific agonists drive mesendodermal differentiation, thereby resolving ligand-specific pathway outputs.

    Evidence KD of WNT11/FZD7/DAAM1 with Rho-ROCK readout and metastasis models (PMID:33082334); Co-IP of Fzd7–Wnt5b with STAT3/YAP1 readout (PMID:32894152); F7L6 bispecific antibody with hPSC differentiation (PMID:33331818)

    PMID:32894152 PMID:33082334 PMID:33331818

    Open questions at the time
    • Structural basis for how FZD7 selects between DAAM1-PCP and Dvl-β-catenin outputs unknown
    • Whether STAT3 activation is direct or through intermediary kinases not fully resolved
  7. 2020 High

    Discovery that YTHDF1 promotes FZD7 mRNA translation in an m6A-dependent manner, and that LRP6 ectodomain is required for CDDO-Me-induced FZD7 degradation, established both translational and post-translational layers of FZD7 regulation.

    Evidence YTHDF1 KD/OE with m6A analysis and FZD7 protein readout in gastric cancer (PMID:32788173); LRP6 ectodomain deletion with FZD7 ubiquitination/stability assay (PMID:32015160)

    PMID:32015160 PMID:32788173

    Open questions at the time
    • Identity of the m6A writer depositing marks on FZD7 mRNA not determined
    • Whether LRP6-dependent degradation operates in normal (non-pharmacological) contexts unclear
  8. 2021 High

    Identification of circACTN4/YBX1-driven transcriptional activation of FZD7 in cholangiocarcinoma added a circular RNA regulatory axis to the growing inventory of FZD7 transcriptional controls.

    Evidence RNA pulldown, mass spectrometry, ChIP, RIP, EMSA, and luciferase reporter identifying circACTN4–YBX1–FZD7 promoter axis

    PMID:34509526

    Open questions at the time
    • Whether circACTN4-YBX1 regulation of FZD7 operates outside cholangiocarcinoma unknown
    • Relative contribution of this axis versus ΔNp63 or BCL6 in the same cell type not assessed
  9. 2023 Medium

    Demonstrating that Vangl1–Fzd7 complex formation at the leading edge of glioblastoma cells drives PCP-mediated invasion, and that BCL6 directly represses FZD7 transcription to promote ferroptosis, further defined tissue-specific regulatory and effector circuits.

    Evidence Co-IP of Vangl1–Fzd7 with Rho GTPase and intracranial xenograft (PMID:37336284); ChIP of BCL6 at FZD7 promoter with ferroptosis markers (PMID:37060074)

    PMID:37060074 PMID:37336284

    Open questions at the time
    • How Vangl1–Fzd7 complex is spatially restricted to leading edge not mechanistically defined
    • Whether BCL6-mediated FZD7 repression occurs in non-gastric tissues unknown
    • Single-lab studies for each finding
  10. 2024 High

    Cryo-EM structures of full-length FZD7 in complex with C. difficile TcdB revealed that CROPs domain rearrangement is essential for toxin–receptor engagement, providing the first high-resolution structural view of full-length FZD7 in a receptor complex and explaining bezlotoxumab's mechanism of action.

    Evidence Cryo-EM of TcdB–FZD7 complex, live-cell binding assay, bezlotoxumab competition

    PMID:38308843

    Open questions at the time
    • No structure of FZD7 in complex with a Wnt ligand or Dvl
    • Whether CROPs rearrangement mimics any aspect of physiological FZD7 activation unknown
  11. 2025 Medium

    Receptor-selective agonists demonstrated that FZD7 and FZD2 activate β-catenin with different kinetics and specify distinct mesoderm subtypes, and BRAF-phosphorylated KIAA1429 stabilizes FZD7 protein to drive Wnt activation, revealing non-redundancy among closely related FZDs and a new post-translational stabilization mechanism.

    Evidence FZD7- vs FZD2-selective antibody agonists with hPSC mesoderm differentiation (PMID:39824186); Co-IP of KIAA1429–FZD7 with FZD7 stability assay in CRC (PMID:40611274)

    PMID:39824186 PMID:40611274

    Open questions at the time
    • Structural basis for differential FZD7 vs FZD2 signaling kinetics unknown
    • Whether KIAA1429 stabilization of FZD7 is m6A-dependent or independent not resolved
    • Single-lab findings awaiting independent replication

Open questions

Synthesis pass · forward-looking unresolved questions
  • A high-resolution structure of FZD7 bound to a native Wnt ligand and intracellular transducer (Dvl or G protein) is needed to explain how a single receptor selects between canonical β-catenin, PCP, and Gαs/PI3K signaling outputs in a ligand-dependent manner.
  • No Wnt–FZD7–effector ternary complex structure exists
  • Molecular determinants of pathway selectivity at the receptor level remain undefined
  • In vivo requirement for FZD7 in adult tissue homeostasis beyond angiogenesis not systematically addressed

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 6 GO:0098772 molecular function regulator activity 3
Localization
GO:0005886 plasma membrane 5
Pathway
R-HSA-162582 Signal Transduction 9 R-HSA-1643685 Disease 5 R-HSA-1266738 Developmental Biology 2
Partners
DAAM1DVL1GIPC2KIAA1429LRP6RSPO2VANGL1ZNRF3
Complex memberships
FZD7–Gαs–PI3K complexFZD7–LRP6 Wnt signalosomeFZD7–Vangl1 PCP complex

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 FZD7 knockdown in TNBC cells suppresses canonical Wnt signaling, evidenced by loss of nuclear β-catenin accumulation and decreased TCF7 transcriptional activity, establishing FZD7 as a required receptor for canonical Wnt/β-catenin pathway activation in triple-negative breast cancer. shRNA knockdown, β-catenin nuclear localization assay, TCF7 reporter assay, xenograft tumor model Oncogene High 21532620
2011 Wnt7a binds Fzd7 and directly activates the Akt/mTOR anabolic growth pathway in differentiated myofibers through a complex containing Gαs and PI(3)K, independent of IGF-receptor activation, demonstrating a non-canonical Wnt7a-Fzd7 signaling axis distinct from its planar cell polarity role in satellite stem cells. Co-immunoprecipitation (Fzd7 complex with Gαs and PI(3)K), Wnt7a treatment of myotubes, PI3K inhibitor, KO/KD with Akt/mTOR readout Nature cell biology High 22179044
2014 ΔNp63 transcription factor promotes mammary stem cell activity and basal breast cancer tumor-initiating ability by directly enhancing Fzd7 expression, thereby increasing Wnt signaling. Gain/loss-of-function of ΔNp63, Fzd7 expression analysis, mammary stem cell activity assays, tumor-initiating cell assays Nature cell biology High 25241036
2014 FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells; a FZD7-specific Fab antibody blocks Wnt3a signaling by downregulating FZD7 protein levels, and shRNA-mediated knockdown disrupts the pluripotent state, demonstrating that hESCs require endogenous WNT/β-catenin signaling through FZD7. shRNA knockdown, FZD7-specific Fab antibody blocking, Wnt3a treatment, pluripotency marker analysis Proceedings of the National Academy of Sciences of the United States of America High 24474766
2008 FZD7 is highly expressed in human embryonic stem cells, and shRNA-mediated knockdown induces colony morphology changes and rapid loss of OCT4 expression, identifying FZD7 as a component of hESC self-renewal signaling. shRNA knockdown, quantitative RT-PCR, flow cytometry, morphological analysis Biological chemistry Medium 18681827
2014 FZD7 knockdown in Stem-A ovarian cancer cells causes actin cytoskeletal rearrangement via reciprocal regulation of RhoA and Rac1 (reduced RhoA activity, increased Rac1 activity), changes in phospho-myosin light chain distribution, and increased TopFlash reporter activity, establishing FZD7 involvement in the non-canonical Wnt/PCP pathway through casein kinase 1ε. siRNA knockdown, RhoA/Rac1 activity assays, phospho-MLC immunofluorescence, TopFlash reporter assay Cell death & disease Medium 25032869
2016 Fzd7 expressed by endothelial cells controls postnatal angiogenesis via activation of Dvl/β-catenin signaling, acting upstream of Notch signaling to regulate Dll4 and Jagged1 expression; endothelial-specific deletion of fzd7 (fzd7ECKO) delays retinal plexus formation due to impaired tip cell phenotype and decreased stalk cell proliferation, rescued by LiCl treatment. Conditional endothelial KO (fzd7ECKO mice), retinal vascular imaging, LiCl pharmacological rescue, Dvl1/3 double KO comparison Arteriosclerosis, thrombosis, and vascular biology High 27758766
2017 RSPO2 physically interacts with Fzd7 and promotes ZNRF3-mediated ubiquitination and degradation of cell-surface Fzd7, suppressing downstream PKC/ERK signaling; Wnt5a prevents Fzd7 degradation, and RSPO2 antagonizes Wnt5a-driven noncanonical Wnt signaling by blocking Wnt5a binding to Fzd7. Co-immunoprecipitation, ubiquitination assay, ZNRF3 involvement, PKC/ERK signaling readout, Wnt5a competitive binding Cancer letters High 28600110
2020 YTHDF1 promotes translation of FZD7 mRNA in an m6A-dependent manner, leading to hyperactivation of the Wnt/β-catenin pathway; mutated YTHDF1 further enhances FZD7 expression and gastric carcinogenesis. YTHDF1 knockdown/overexpression, m6A methylation analysis, FZD7 protein translation assay, Wnt/β-catenin pathway readout, in vitro and in vivo tumor models Cancer research High 32788173
2021 circACTN4 recruits Y-box binding protein 1 (YBX1) to stimulate FZD7 transcription in intrahepatic cholangiocarcinoma, identified via RNA pulldown, mass spectrometry, ChIP, RIP, EMSA, and luciferase reporter assays. RNA pulldown, mass spectrometry, chromatin immunoprecipitation (ChIP), RNA-binding protein immunoprecipitation (RIP), EMSA, luciferase reporter assay Journal of hepatology High 34509526
2020 WNT11-FZD7-DAAM1 signaling activates Rho-ROCK1/2-Myosin II and plays a crucial role in amoeboid melanoma invasion, tumor-initiating potential, and distant metastasis formation. KD of WNT11/FZD7/DAAM1, Rho-ROCK-Myosin II pathway readout, invasion assays, in vivo metastasis models Nature communications High 33082334
2020 Fzd7 in breast cancer cells interacts with Wnt5a/b to modulate phosphorylated STAT3, Smad3, and YAP1; Fzd7-Wnt5b signaling upregulates Col6a1, which mediates Fzd7-Wnt5b-induced mesenchymal-like stemness, establishing a non-canonical Wnt pathway role for Fzd7 in EMT and stemness. Co-IP (Fzd7 with Wnt5a/b), KD of Fzd7/Wnt5b/Col6a1, immunofluorescence, mammosphere formation, xenograft, lung metastasis assay Cell communication and signaling : CCS Medium 32894152
2022 GIPC2 directly binds the WNT co-receptor Fzd7 through its PDZ domain, enabling activation of WNT-β-catenin cascades and stimulating prostate cancer metastasis. Co-immunoprecipitation, PDZ domain binding assay, GIPC2 KD with WNT-β-catenin readout, in vitro and in vivo metastasis assays Oncogene Medium 35347223
2019 FZD7 regulates TWIST1 expression through epigenetic modifications of H3K4me3 and H3K27ac at the TWIST1 proximal promoter; the FZD7-TWIST1 axis controls BCL2 expression to confer anoikis resistance in ovarian cancer cells. FZD7 KD, chromatin histone modification analysis (H3K4me3/H3K27ac at TWIST1 promoter), TWIST1 overexpression rescue, BCL2 expression assay, anoikis resistance assays Molecular oncology Medium 30548372
2016 Notch3, but not Notch1, 2, or 4, uniquely regulates FZD7 expression in human breast epithelial cells through a non-canonical (CSL-independent) Notch signaling mechanism. Gain and loss-of-function of NOTCH1-4, FZD7 expression analysis, CSL-independence assay Stem cells and development Medium 26847503
2018 GCM1 transcription factor promotes trophoblast cell migration through transcriptional activation of WNT10B; WNT10B then signals through FZD7 as its cognate receptor to upregulate Rac1-mediated cytoskeletal remodeling and cell migration; SFRP3 from decidual cells blocks WNT10B-FZD7 interaction to suppress migration. GCM1 target gene identification, WNT10B-FZD7 interaction (co-immunoprecipitation/functional blocking), Rac1 activity assay, SFRP3 competitive binding, trophoblast migration assays FASEB journal Medium 29979633
2020 Selective engagement of FZD7 and LRP6 by engineered bispecific antibody F7L6 is sufficient to potently activate WNT/β-catenin signaling and drive mesendodermal differentiation of human pluripotent stem cells, demonstrating that FZD7 specifically can transduce canonical Wnt signals. Engineered FZD7-specific scFv bispecific agonist (F7L6), WNT/β-catenin reporter assay, transcriptional profiling of hPS cell differentiation, comparison to Wnt3a eLife High 33331818
2020 CDDO-Me inhibits Wnt/β-catenin signaling by inducing ubiquitination and lysosomal degradation of the LRP6/FZD7 receptor complex; the ectodomain of LRP6 is required for CDDO-Me-induced FZD7 degradation, revealing LRP6-dependent regulation of FZD7 protein stability. Ubiquitination assay, lysosomal pathway inhibitor, LRP6 ectodomain deletion constructs, FZD7 and LRP6 protein stability assays, Wnt target gene readout The Journal of pharmacology and experimental therapeutics Medium 32015160
2023 BCL6 directly binds and transcriptionally represses FZD7, reducing Wnt/β-catenin signaling and promoting ferroptosis via the FZD7/β-catenin/TP63/GPX4 pathway in gastric cancer. ChIP assay (BCL6 binding to FZD7 promoter), dual luciferase reporter assay, rescue experiments, ferroptosis markers (lipid peroxidation, MDA, Fe2+), GPX4 expression Cell & bioscience Medium 37060074
2024 Cryo-EM structures of Clostridioides difficile toxin B (TcdB) alone and in complex with full-length FZD7 reveal that large structural rearrangements of the combined repetitive polypeptide (CROPs) domain are required for FZD7 binding; bezlotoxumab (FDA-approved antibody) favors the apo-TcdB conformation and disrupts FZD7 binding. Cryo-EM structure determination of TcdB-FZD7 complex, live-cell binding assay, bezlotoxumab competition assay Cell reports High 38308843
2023 Vangl1 and Fzd7 form a complex at the leading edge of migrating GBM cells, promoting actin cytoskeletal rearrangements, Rho GTPase engagement, and tumor cell proliferation, migration, and invasiveness via non-canonical Wnt/PCP signaling. Co-immunoprecipitation (Vangl1/Fzd7 complex), KD of FZD7 and Vangl1, Rho GTPase assays, actin dynamics imaging, intracranial xenograft model Cancer letters Medium 37336284
2023 Structure-based ligand discovery targeting the transmembrane domain (TMD) of FZD7 identified compound F7H as an antagonist (IC50 = 1.25 μM); molecular docking, MD simulation, and FEP calculations defined the binding pocket and key residue interactions. Virtual screening, molecular docking, molecular dynamics simulation, free energy perturbation, functional Wnt antagonism assay Journal of medicinal chemistry Medium 37669317
2024 SIRT7 promotes FZD7 expression via transcription factor PU.1 upregulation, and FZD7 is essential for SIRT7-mediated β-catenin stabilization (preventing its association with the destruction complex) and activation of canonical Wnt signaling in hepatocellular carcinoma. SIRT7/PU.1/FZD7 KD, nuclear cytosol fractionation, β-catenin ubiquitination/stability assay, TopFlash reporter, ChIP-PCR for PU.1 at FZD7 promoter Life sciences Medium 39542206
2025 FZD7 and FZD2 activate β-catenin signaling with different kinetics in hPSCs; FZD7 activation promotes both paraxial and lateral mesoderm differentiation while FZD2 favors only paraxial mesoderm, demonstrating non-redundant roles of these closely related FZD receptors in mesoderm specification. Selective FZD7- and FZD2-specific antibody-based agonists, β-catenin signaling kinetics measurement, directed differentiation of hPSCs, transcriptional profiling of mesoderm subtypes Stem cell reports Medium 39824186
2024 WNT7A activates FZD7 to stimulate the JAK1/STAT3 signaling pathway (not the canonical Wnt-β-catenin pathway) in head and neck squamous cell carcinoma, promoting cell proliferation, self-renewal, and resistance to apoptosis. WNT7A overexpression, β-catenin pathway reporter (negative), FZD7/JAK1/STAT3 pathway analysis, PDX tumor model International journal of oral science Medium 38246919
2022 FZD7 silencing in pancreatic cancer attenuates TGF-β1-induced EMT and reduces stemness markers (ABCG2, CD24, CD44), demonstrating that FZD7 participates in both canonical Wnt and TGF-β/SMAD3 signaling to drive EMT and cancer stem cell properties. shRNA FZD7 silencing, TGF-β1 stimulation, EMT marker Western blot, sphere formation, flow cytometry for CD24/CD44, β-catenin activation assay Molecular medicine (Cambridge, Mass.) Medium 35854234
2020 Wnt5a upregulates ABCG2 expression through FZD7 in pancreatic cancer cells, and FZD7 silencing or inhibition abolishes Wnt5a-induced ABCG2 upregulation and gemcitabine resistance, placing FZD7 as the essential receptor for Wnt5a-driven drug resistance. Recombinant Wnt5a treatment, siRNA FZD7 silencing, FZD7 inhibitor, ABCG2 expression assay, gemcitabine resistance assay Molecular medicine reports Medium 33200805
2019 Fibronectin promotes limbal epithelial stem cell self-renewal by facilitating Wnt11-Fzd7 interaction and activating the non-canonical Wnt11/Fzd7/ROCK pathway to modulate cell cycle regulators. Fibronectin treatment, Wnt11/Fzd7 co-expression and interaction analysis, ROCK1/2 activity assay, cell cycle analysis, stemness assays Experimental eye research Low 31150636
2016 FZD7 overexpression in glioma activates TAZ (transcriptional coactivator with PDZ-binding motif), and TAZ is required for FZD7-driven glioma cell proliferation, placing TAZ as a downstream effector of FZD7 signaling. FZD7 overexpression/KD, TAZ activity assay, TAZ KD rescue experiment, xenograft proliferation assay Oncotarget Medium 27852064
2025 KIAA1429 phosphorylation by BRAF drives its cytoplasmic accumulation, where it binds and stabilizes FZD7, leading to WNT pathway activation, enhanced cancer stemness and oxaliplatin resistance in colorectal cancer. Co-immunoprecipitation (KIAA1429-FZD7), IP-MS, immunofluorescence (nuclear/cytoplasmic distribution), FZD7 stability assay, in vitro and in vivo drug resistance experiments Journal of experimental & clinical cancer research : CR Medium 40611274

Source papers

Stage 0 corpus · 84 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 230 21532620
2020 YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer research 197 32788173
2011 Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nature cell biology 193 22179044
2014 ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nature cell biology 190 25241036
2021 Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. Journal of hepatology 181 34509526
2001 Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. International journal of oncology 136 11408930
2014 FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. Cell death & disease 108 25032869
2014 The WNT receptor FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 96 24474766
2018 Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells. Phytomedicine : international journal of phytotherapy and phytopharmacology 87 29747752
2015 MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 79 25976503
2020 WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nature communications 71 33082334
2011 Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 67 21472018
2019 miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway. Journal of experimental & clinical cancer research : CR 59 31419987
2017 RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway. Cancer letters 59 28600110
2014 MiR-199a regulates cell proliferation and survival by targeting FZD7. PloS one 56 25313882
2001 Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer. Life sciences 50 11798016
2008 The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biological chemistry 48 18681827
2021 LncRNA HOTAIR promotes breast cancer progression through regulating the miR-129-5p/FZD7 axis. Cancer biomarkers : section A of Disease markers 46 33104019
2018 hsa_circ_0000177-miR-638-FZD7-Wnt Signaling Cascade Contributes to the Malignant Behaviors in Glioma. DNA and cell biology 42 30010402
2016 MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. Biochemical and biophysical research communications 39 27815069
2019 MicroRNA-488 inhibits endometrial glandular epithelial cell proliferation, migration, and invasion in endometriosis mice via Wnt by inhibiting FZD7. Journal of cellular and molecular medicine 35 30729701
2016 Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget 35 27852064
2022 FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling. Molecular medicine (Cambridge, Mass.) 34 35854234
2018 LncRNA AWPPH promotes the growth of triple-negative breast cancer by up-regulating frizzled homolog 7 (FZD7). Bioscience reports 33 30333256
2017 Antitumor effect of miR-27b-3p on lung cancer cells via targeting Fzd7. European review for medical and pharmacological sciences 31 29028088
2021 Circular RNA circCSPP1 knockdown attenuates doxorubicin resistance and suppresses tumor progression of colorectal cancer via miR-944/FZD7 axis. Cancer cell international 30 33663510
2021 Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD7 in cancer. Drug discovery today 30 34915171
2019 LncRNA AWPPH promotes osteosarcoma progression via activation of Wnt/β-catenin pathway through modulating miR-93-3p/FZD7 axis. Biochemical and biophysical research communications 28 31092328
2017 MicroRNA-27b inhibits cell proliferation in oral squamous cell carcinoma by targeting FZD7 and Wnt signaling pathway. Archives of oral biology 28 28735227
2016 Fzd7 (Frizzled-7) Expressed by Endothelial Cells Controls Blood Vessel Formation Through Wnt/β-Catenin Canonical Signaling. Arteriosclerosis, thrombosis, and vascular biology 28 27758766
2007 Comparative integromics on FZD7 orthologs: conserved binding sites for PU.1, SP1, CCAAT-box and TCF/LEF/SOX transcription factors within 5'-promoter region of mammalian FZD7 orthologs. International journal of molecular medicine 28 17273804
2021 A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models. Molecular cancer therapeutics 27 34667113
2020 Non-canonical Fzd7 signaling contributes to breast cancer mesenchymal-like stemness involving Col6a1. Cell communication and signaling : CCS 27 32894152
2019 The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. Molecular oncology 27 30548372
2010 Variable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment. Developmental dynamics : an official publication of the American Association of Anatomists 27 19655379
2022 GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling. Oncogene 26 35347223
2021 Fzd7/Wnt7b signaling contributes to stemness and chemoresistance in pancreatic cancer. Cancer medicine 26 33934523
2022 CircRNA_Maml2 promotes the proliferation and migration of intestinal epithelial cells after severe burns by regulating the miR-93-3p/FZD7/Wnt/β-catenin pathway. Burns & trauma 23 35265724
2020 Selective activation of FZD7 promotes mesendodermal differentiation of human pluripotent stem cells. eLife 22 33331818
2019 Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway. Oncology letters 21 31289540
2016 Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor. Bioengineered 21 27849134
2019 Fibronectin regulates the self-renewal of rabbit limbal epithelial stem cells by stimulating the Wnt11/Fzd7/ROCK non-canonical Wnt pathway. Experimental eye research 20 31150636
2022 An investigation of bacteriocin nisin anti-cancer effects and FZD7 protein interactions in liver cancer cells. Chemico-biological interactions 19 36084725
2020 CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex. The Journal of pharmacology and experimental therapeutics 19 32015160
2018 Aberrant Expression of miR-142-3p and its Target Gene HMGA1 and FZD7 in Breast Cancer and its Clinical Significance. Clinical laboratory 19 29945308
2016 FZD7 regulates BMSCs-mediated protection of CML cells. Oncotarget 18 26716419
2023 The malignancy suppression and ferroptosis facilitation of BCL6 in gastric cancer mediated by FZD7 repression are strengthened by RNF180/RhoC pathway. Cell & bioscience 17 37060074
2020 Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells. Molecular medicine reports 17 33200805
2018 Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes. Breast cancer research and treatment 17 29411237
2022 Exosomal FZD-7 Expression Is Modulated by Different Lifestyle Interventions in Patients with NAFLD. Nutrients 15 35334792
2018 Structural and dynamic characterization of human Wnt2-Fzd7 complex using computational approaches. Journal of molecular modeling 14 30191337
2020 CircSAMD4A regulates cell progression and epithelial‑mesenchymal transition by sponging miR‑342‑3p via the regulation of FZD7 expression in osteosarcoma. International journal of molecular medicine 13 32319545
2016 Notch-Induced Expression of FZD7 Requires Noncanonical NOTCH3 Signaling in Human Breast Epithelial Cells. Stem cells and development 13 26847503
2005 Comparative genomics on Fzd7 orthologs. International journal of molecular medicine 12 15870913
2024 WNT7A promotes tumorigenesis of head and neck squamous cell carcinoma via activating FZD7/JAK1/STAT3 signaling. International journal of oral science 11 38246919
2020 MicroRNA-1 Modulates Chondrocyte Phenotype by Regulating FZD7 of Wnt/ β-Catenin Signaling Pathway. Cartilage 11 33215510
2023 A complex of Wnt/planar cell polarity signaling components Vangl1 and Fzd7 drives glioblastoma multiforme malignant properties. Cancer letters 10 37336284
2018 SFRP3 negatively regulates placental extravillous trophoblast cell migration mediated by the GCM1-WNT10B-FZD7 axis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 10 29979633
2017 MicroRNA‑613 inhibits proliferation and invasion of renal cell carcinoma cells through targeting FZD7. Molecular medicine reports 10 29067457
2024 Structural and functional insight into the interaction of Clostridioides difficile toxin B and FZD7. Cell reports 9 38308843
2023 Structure-Based Ligand Discovery Targeting the Transmembrane Domain of Frizzled Receptor FZD7. Journal of medicinal chemistry 9 37669317
2022 MiR-1-3p enhances the sensitivity of ovarian cancer cells to ferroptosis by targeting FZD7. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 9 36481629
2016 Short hairpin RNA silencing of TGF-βRII and FZD-7 synergistically suppresses proliferation and metastasis of hepatocellular carcinoma cells. Oncology letters 7 26998118
2024 FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer. ACS omega 6 38559981
2019 Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response. Disease markers 6 31827644
2024 SIRT7 stabilizes β-catenin and promotes canonical Wnt activation via upregulating FZD7. Life sciences 5 39542206
2023 FZD7, Regulated by Non-CpG Methylation, Plays an Important Role in Immature Porcine Sertoli Cell Proliferation. International journal of molecular sciences 5 37047150
2025 YTHDF1-mediated m6A modification promotes cisplatin resistance in ovarian cancer via the FZD7/Wnt/β-catenin pathway. Apoptosis : an international journal on programmed cell death 4 40281310
2025 Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAFV600E-mutated colorectal cancer. Journal of experimental & clinical cancer research : CR 4 40611274
2024 HAS2 facilitates glioma cell malignancy and suppresses ferroptosis in an FZD7-dependent manner. Cancer science 4 38816349
2025 Silencing of FZD7 Inhibits Endometriotic Cell Viability, Migration, and Angiogenesis by Promoting Ferroptosis. Cell biochemistry and biophysics 3 39797998
2025 Selective activation of FZD2 and FZD7 reveals non-redundant function during mesoderm differentiation. Stem cell reports 2 39824186
2025 G-protein-coupled receptor FZD7 as a therapeutic target in glioblastoma: Multi-cohort validation and identification of Cycloartobiloxanthone as an inhibitor. Bioorganic chemistry 2 40412223
2023 FZD7: A potential biomarker for endometriosis. Medicine 2 37800830
2023 Mechanism of miR-548b-5p down-regulating FZD7 to impede the migratory and invasive behavior of gastric carcinoma cells. Cellular and molecular biology (Noisy-le-Grand, France) 2 38279460
2022 Anti-tumor activity of a recombinant soluble Fzd7 decoy receptor in human gastric and colon cancer cells. Iranian journal of basic medical sciences 2 35655594
2022 Antitumor effect and mechanism of FZD7 polypeptide vaccine. Frontiers in oncology 2 36276155
2021 A missense mutation in the FZD7 gene is associated with dilution of the red areas of the coat in Montbéliarde cattle. Animal genetics 2 33686687
2019 The Function of Lgr5+ Cells in the Gastric Antrum Does Not Require Fzd7 or Myc In Vivo. Biomedicines 2 31288403
2025 N6-methyladenosine regulated FZD7 inhibits ferroptosis in endometriosis via β-catenin/SLC7A11 pathway. Free radical biology & medicine 1 41241001
2025 LINC00888 Promotes Gastric Cancer Growth and Metastasis by Sponging miR-145-5p to Regulate FZD7 Expression. Combinatorial chemistry & high throughput screening 0 41177801
2025 FZD7 expression marks mammary tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America 0 41218118
2025 USP30-AS1 Dictates Breast Cancer Cell Fate and Chemoresistance via a miR-3646/FZD7/Wnt/β-Catenin Circuit. Current issues in molecular biology 0 41614739
2024 [Retracted] Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway. Oncology letters 0 38690102